Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (24992)	8/29/1998 11:33:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

Roy and Bob Z ----- RE Ligand's Potential Markets I gave this link before, so pardon the repetition - but the information Roy asked about is presented compactly. Once inside this link - Ligand Corporate Profile (from Research Magazine) researchmag.com; CLICK Potential Markets. ---------------------- They mention only 2 drugs, but list indications and numbers (I cut in the following, because they were working on their site as I was typing -- and who knows if the link is still there . . .) Potential Markets TargretinTM (LGD1069): NEW PATIENTS PER YEAR (U.S.) Actinic keratoses: 1.5 million Diabetes (Type II): 15 million (total patients) Head and neck cancer: 39,750 Kaposi's sarcoma: 22,200 Lung cancer: 169,900 Ovarian cancer: 26,600 Prostate cancer: 244,000 Skin lymphoma: 6,000 ------------------ PanretinTM* (ALRT1057): NEW PATIENTS PER YEAR (U.S.) APL: 2,500 Breast cancer: 182,000 Kaposi's sarcoma: 22,200 Ovarian cancer: 26,600 Prostate cancer: 244,000 Severe psoraisis: 157,000 --------------- To All: Do you have any corrections/comments about Research Mag's list for these two drugs?